Cortical plasticity of Visual Evoked Potentials in Neurofibromatosis Type 1 patients
- Conditions
- Neurofibromatosis type 1Von Recklinghausen disease1002929910009841
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 56
- Age; between 18-55 years at inclusion
- Being capable of providing written informed consent
- Ability to understand the Dutch language
- Healthy (no history of neurological or psychiatric disorders)
- NF1 patients with a genetically or clinically confirmed diagnosis
- Use of psychoactive agents
- History of or current presence of neurological or psychiatric disorders
(excluding a history of attention deficit disorder or autism for the NF1
patients)
- Other neurological illness influencing the functioning of the central nervous
system or visual tract involved in the VEP recordings.
- Neurological illness of the peripheral nervous system involving the sensory
or visual function of the eyes.
- Segmental NF1
- Severe visual problems or blindness
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Plasticity as measured by the change in VEP peak amplitudes at T1, T2 and T3<br /><br>after a modulation block of 10 minutes checkerboard reversals compared to the<br /><br>baseline measurements.</p><br>
- Secondary Outcome Measures
Name Time Method <p>- VEPs parameters, such as latency and peak amplitudes of P100, at baseline<br /><br>measurements of patients and controls.<br /><br>- Parameters of visual information processing, such as reaction time, accuracy<br /><br>and speed of the eye movements, using a remote eye tracker<br /><br>- Relationships between cortical plasticity as measured by an increase in VEP<br /><br>peak amplitudes over time, and the parameters of visual information processing. </p><br>